• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.006 -0.024 (-2.33%)
Streaming Delayed Price Updated: 11:28 AM EST, Feb 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NanoViricides, Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >
BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Files Orphan Drug Designation Application for NV-387 in MPox
February 12, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
February 12, 2026
Via ACCESS Newswire
News headline image
NanoViricides Files for Orphan Drug Status as U.S. Measles Cases Surge (MRNA,QNCX)
February 12, 2026
Via AB Newswire
Topics Death
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Files Orphan Drug Designation Application for NV-387 as Measles Treatment
February 10, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
February 10, 2026
Via ACCESS Newswire
BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Mission Matters Podcast Interview With President Anil Diwan
February 02, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres
February 02, 2026
Via ACCESS Newswire
News headline image
NanoViricides to Present at the 3rd Annual DealFlow Discovery Conference
January 20, 2026
Via ACCESS Newswire
BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Need for Broad-Spectrum Antivirals Amid Severe Influenza Season
January 13, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2
January 13, 2026
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Signs Master Services Agreement With Only Orphans Cote for NV-387 Orphan Drug Strategy
December 01, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles
December 01, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Files Quarterly Report Highlighting Broad-Spectrum Antiviral Candidate NV-387
November 17, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
November 17, 2025
Via ACCESS Newswire
News headline image
NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2
November 14, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Closes $6 Million Registered Direct Offering With Concurrent Private Placement of Warrants
November 13, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
November 12, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Announces $6 Million Registered Direct Offering with Concurrent Private Placement of Warrants
November 11, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
November 11, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Receives Regulatory Approval to Begin Phase II Trial of NV-387 for Treatment of MPox in the DRC
November 10, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo
November 10, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Announces Date and Location of 2025 Annual Shareholders Meeting
November 05, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT
November 05, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at Spartan Capital Investor Conference 2025
November 03, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd
November 03, 2025
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights Potent Anti-Measles Results for NV-387 in Proactive Interview
October 29, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive
October 29, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at PODD 2025 Conference in Boston
October 27, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
October 27, 2025
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Strong Antiviral and Lung-Protective Activity of NV-387 Against Measles
October 23, 2025
Via Investor Brand Network
Topics Intellectual Property
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap